HighTower Advisors’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

HighTower Advisors’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-25,820	Closed	-$273K	–	3737
2022 Q4	$273K	Buy	25,820 +2,205	+9%	+$17.8K	﹤0.01%	2544
2022 Q3	$106K	Hold	23,615	–	–	﹤0.01%	2755
2022 Q2	$95K	Sell	23,615 -50	-0.2%	-$237	﹤0.01%	2797
2022 Q1	$174K	Buy	+23,665	New	+$142K	﹤0.01%	2875
2021 Q4	–	Sell	-23,616	Closed	-$151K	–	3552
2021 Q3	$151K	Buy	23,616 +900	+4%	+$5.78K	﹤0.01%	2777
2021 Q2	$191K	Buy	22,716 +6,416	+39%	+$51.8K	﹤0.01%	2682
2021 Q1	$171K	Buy	+16,300	New	+$229K	﹤0.01%	2652
2018 Q4	–	Sell	-35,047	Closed	-$141K	–	2409
2018 Q3	$141K	Buy	+35,047	New	+$139K	﹤0.01%	2010

Other funds holding PRVB

Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

HighTower Advisors's PRVB Position: Q1 2023 in Review

HighTower Advisors sold out of Provention Bio, Inc. Common Stock (PRVB) in Q1 2023, closing a stake of 25,820 shares — an estimated $273K sold.

HighTower Advisors first reported a position in PRVB in Q3 2018 and held it in 8 quarters. The position peaked at $273K in Q4 2022. 182 funds tracked by Wall St. Rank hold PRVB as of Q1 2023.

HighTower Advisors reported no remaining Provention Bio, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
HighTower Advisors sold 25,820 Provention Bio, Inc. Common Stock shares in Q1 2023, an estimated $273K.
HighTower Advisors first reported a position in Provention Bio, Inc. Common Stock in Q3 2018 and held it in 8 quarters.
HighTower Advisors's Provention Bio, Inc. Common Stock position peaked at $273K in Q4 2022.
182 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q1 2023.

Based on HighTower Advisors's 13F filing for Q1 2023, filed 12 May 2023.